Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Significant Decline in Short Interest

Aspira Women’s Health Inc. (NASDAQ:AWH) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 438,500 shares, a drop of 11.8% from the November 30th total of 497,300 shares. Currently, 3.8% of the shares of the company are short sold. Based on an average daily trading volume, of 93,300 shares, the short-interest ratio is currently 4.7 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co bought a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health as of its most recent SEC filing. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

Aspira Women’s Health Stock Performance

AWH stock traded down $0.03 during midday trading on Friday, reaching $0.74. The stock had a trading volume of 149,503 shares, compared to its average volume of 76,360. The firm has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $1.02. Aspira Women’s Health has a 52-week low of $0.67 and a 52-week high of $5.65. The stock has a market cap of $12.37 million, a PE ratio of -0.62 and a beta of 1.39.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Aspira Women’s Health in a research report on Wednesday. They set a “hold” rating for the company.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.